Saturday, 31 October 2026European Markets

CTC ORD SHARES Stock Is 10% Down So Far Today

Loading stream...

(VIANEWS) - Shares of CTC ORD SHARES (AEX-Index: CTCA1.AS) dropped by a staggering 10.53% to €8.50 at 14:07 EST on Wednesday, after five successive sessions in a row of losses. AEX-Index is sliding 0.72% to €773.14, after five consecutive sessions in a row of gains. This seems, as yet, a somewhat bearish trend exchanging session today.

CTC ORD SHARES's last close was €9.50, 5% below its 52-week high of €10.00.

About CTC ORD SHARES

Climate Transition Capital Acquisition I B.V., a special purpose acquisition company, intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with businesses or entities. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, CTC ORD SHARES has a trailing twelve months EPS of €-0.46.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CTC ORD SHARES's stock is considered to be overbought (>=80).

Moving Average

CTC ORD SHARES's value is way below its 50-day moving average of €9.84 and way below its 200-day moving average of €9.83.

Yearly Top and Bottom Value

CTC ORD SHARES's stock is valued at €8.50 at 14:07 EST, way below its 52-week low of €9.55.

More news about CTC ORD SHARES (CTCA1.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com